Hunan Cancer Hospital

Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, cover a land area of 101200 square meters and a construction area of 181200 square meters. Its area for business covers 124600 square meters and its fixed assets attain 1.587 billion Yuan. The Hospital was founded in 1972, passed the national review for “Grade IIIA ” specialized cancer hospital in 1994, was officially designated as “The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University” in 2012, became the first JCI (Joint Commission International)-accredited cancer hospital in China in 2014, became a sister hospital of the MD Anderson Cancer Center (USA) in 2015, was approved to be a national-level standardized training base for resident physicians, successfully passed the on-site examination for the national key specialty development projects during the 12th Five-Year Plan, and ranked in China’s top 100 hospitals for the project of enhancing the competence to diagnose and treat difficult and complicated diseases in 2017. At present, the Hospital has developed into a “Grade IIIA” specialized cancer hospital integrating medical treatment, scientific research, teaching, prevention, and rehabilitation, and is a provincial cancer prevention and treatment research center. The National Drug Clinical Trial Institutions, Hunan Provincial Cancer Medical Center, the Provincial Institute of Cancer Research, the Provincial Office of Cancer Prevention Research, the Hunan Provincial Anti-Cancer Association, Hunan International School for Enterostomal Therapists, and the journal of Anti-Tumor Pharmacy are all affiliated with the Hospital. The Hospital has established the first province-wide union of specialized cancer hospital involving medical institutions at the provincial, municipal and county level and incorporating more than 170 members. In 2017, the Hospital had 372,781 outpatient attendances, increasing by 4.06% year on year; 93,763 admissions, increasing by 5.5% year on year; 16,870 operations on inpatients, increasing by 5.92% year on year; a 116.98% rate of utilization of hospital beds, increasing by 6.95% year on year; a bed turnover ratio of 48.01%, increasing by 5.49% year on year; and an average hospital stay of 9.79 days, nearly the same as that of the previous year. I. Perfect Organizational Structure and Advanced Equipment and Facilities The Hospital has 1,490 beds as planned, 41 clinical departments, and 13 medico-technical departments. Up to December 31, 2017, the Hospital had 2,189 in-service employees, 1,925 professional and technical personnel, proximately accounting for 87.93% of the entire staff, 549 employees with senior professional titles, proximately accounting for 25.07%, 12 experts receiving the special government allowance granted by the State Council, 2 experts receiving the special allowance granted by the provincial government, 1 “Famous Doctor of Xiangya Hospital”, 14 “The 121 Project” experts, 9 “The 225 Project” experts, and 2 experts of the provincial “Hundred Talents Program”. The Hospital has world-class, state-of-the-art instrumentation and equipment, the first PET/CT and the first helical tomotherapy (Tomo®Therapy) system in the province, including a number of linear accelerators such as the high precision, high dose rate Trilogy linear accelerator, a fully automatic biochemistry analyzer, an Infinia ECT, a 3.0T nuclear magnetic resonance spectrometer, a radiotherapy simulator CT scanner, an imported multi-slice helical CT scanner, a full-field digital gastrointestinal endoscopy machine, an imported full-field digital mammography, a high-definition electronic thoracoscope and electronic endoscope, an imported real-time four-dimensional color doppler ultrasound diagnostic apparatus, etc., and 127 apparatuses worth of more than RMB 1 million. II. Leading Specialty Competence and Complete Range of Treatment Methods At present, the Hospital has 3 national-level key clinical specialties (Oncology, Specialist Care, and Integrated Chinese and Western Medicine), 7 provincial-level key clinical specialties (Gynecology, Medical Imaging, Clinical Pharmacy, General Surgery, Thoracic Surgery, Radiotherapy, and Anesthesiology). Based on the development of the specialty of oncology and on the principle of comprehensive treatment, 16 treatment centers are set up according to disease categories, each of which has a standardized scheme for diagnosis and treatment. III. Progressive Scientific Research and Recognized Competence In 2017, the Hospital was awarded 63 government-sponsored scientific research projects, won a first, a second, and a third prize of the Hunan Medical Science and Technology Award, achieving a breakthrough in winning a first prize of the Hunan Medical Science and Technology Award; won a first and a second prize of Technology Award of Hunan Nursing Association, published 307 academic papers, 53 of which were included in SCI, with an average impact factor of 139.245. At present, the Hospital has 13 doctoral advisors and 68 Master’s advisors. The Hospital has a post-doctoral research station, a central laboratory and laboratory animal center with advanced equipment, etc, and 7 medical research and treatment centers. The Hospital is a national clinical pharmacist training base, a provincial standardized cancer treatment training base, a provincial backbone physicians training base, a provincial specialized oncology nurse standardized training base, and a provincial PICC specialized nurse standardized training base. IV. Furthering International Collaboration, Enhancing International Influence The Hospital extensively collaborates with a number of countries and regions such as the United States, France, Hong Kong, etc, and arranges for reciprocal expert visits, lectures, researches and exchanges in the areas of specialty, management, culture, etc. The Hospital, relying on being a sister hospital of The MD Anderson Cancer Center (USA), successfully signed memorandums of understanding with Israel’s two major top medical institutions Rabin Medical Center and Shaare Zedek Medical Center in 2017; signed a cooperation agreement with Northwestern University of the U.S.A., becoming the hospital’s only overseas gynecological oncology diplomate training base; has also become a friendship hospital with the Centre Regional de Lutte Contre Le Cancer (CRLC) in France, and established long-term partnerships with a number of cancer prevention and treatment research institutes such as Institute Curie in France, the University of Minnesota Medical School, the UCSF School of Nursing (U.S.A), etc. V. Strengthen Implementation of Cancer Prevention and Control and Reduce Incidence Rate Cancer prevention and control: National public hygiene programs mainly undertaken by the Hospital in recent years cover early diagnosis and treatment program on five cancers in the city: Hunan Province has implemented high-risk appraisal on over 250,000 people, accomplished clinical screening on more than 60,000 people, checked out over 480 suspected cancers and more than 4400 precancerous lesions. Moreover, each month, the Hospital would regularly compile Brief Message on Early Diagnosis and Early Prevention of Cancer in Cities of Hunan Province. Registration of tumor morbidity and death in the province: at present, Hunan Province has 29 cancer registration sites. The number of coverage grew from 1.27 million in 2009 to 17.57 million, accounting for 24.5% of the total population of the province. Early diagnosis and treatment of upper gastrointestinal tract cancer in rural area: since its implementation, its task was to carry out endoscope check on people with high risks aged 40-69 in rural areas in the province. By now, it has conducted gastroscope screening on more than 16000 rural members. Follow-up visits on patients after surgery for non-small cell lung cancer: the Hospital would conduct follow-up visits on patients after surgery for non-small cell lung cancer twice on the yearly basis. Requirements for follow-up visit: chest CT and B-mode ultrasound on the abdomen. By June 2018, more than 1000 people were included in the program and over 1200 people were followed up (450 people per time).